share_log

Jilin Aodong Pharmaceutical Group's (SZSE:000623) Problems Go Beyond Poor Profit

Jilin Aodong Pharmaceutical Group's (SZSE:000623) Problems Go Beyond Poor Profit

吉林奥东药业集团(SZSE: 000623)的问题不仅仅是利润不佳
Simply Wall St ·  04/25 18:33

Jilin Aodong Pharmaceutical Group Co., Ltd.'s (SZSE:000623) stock wasn't much affected by its recent lackluster earnings numbers. We did some digging, and we believe that investors are missing some worrying factors underlying the profit figures.

吉林奥东药业集团有限公司s(深圳证券交易所股票代码:000623)的股票并未受到其最近疲软的收益数字的太大影响。我们进行了一些挖掘,我们认为投资者遗漏了构成利润数据的一些令人担忧的因素。

earnings-and-revenue-history
SZSE:000623 Earnings and Revenue History April 25th 2024
SZSE: 000623 2024 年 4 月 25 日的收益和收入历史记录

One essential aspect of assessing earnings quality is to look at how much a company is diluting shareholders. Jilin Aodong Pharmaceutical Group expanded the number of shares on issue by 5.3% over the last year. That means its earnings are split among a greater number of shares. Per share metrics like EPS help us understand how much actual shareholders are benefitting from the company's profits, while the net income level gives us a better view of the company's absolute size. Check out Jilin Aodong Pharmaceutical Group's historical EPS growth by clicking on this link.

评估收益质量的一个重要方面是研究一家公司在多大程度上稀释了股东。吉林奥东药业集团的已发行股票数量比去年增加了5.3%。这意味着其收益将分配给更多的股票。每股收益等每股指标可以帮助我们了解实际股东从公司的利润中受益的程度,而净收入水平则使我们能够更好地了解公司的绝对规模。点击此链接,查看吉林奥东药业集团的历史每股收益增长。

How Is Dilution Impacting Jilin Aodong Pharmaceutical Group's Earnings Per Share (EPS)?

稀释如何影响吉林奥东药业集团的每股收益(EPS)?

Unfortunately, Jilin Aodong Pharmaceutical Group's profit is down 15% per year over three years. Even looking at the last year, profit was still down 18%. Sadly, earnings per share fell further, down a full 17% in that time. So you can see that the dilution has had a bit of an impact on shareholders.

不幸的是,吉林奥东药业集团的利润在三年内每年下降15%。即使从去年来看,利润仍下降了18%。可悲的是,收入 每股 进一步下跌,当时下跌了整整17%。因此,你可以看到稀释对股东产生了一些影响。

In the long term, if Jilin Aodong Pharmaceutical Group's earnings per share can increase, then the share price should too. However, if its profit increases while its earnings per share stay flat (or even fall) then shareholders might not see much benefit. For the ordinary retail shareholder, EPS is a great measure to check your hypothetical "share" of the company's profit.

长期来看,如果吉林奥东药业集团的收益 每股 可以上涨,那么股价也应该上涨。但是,如果其利润增加而每股收益持平(甚至下降),那么股东可能看不到太多好处。对于普通散户股东来说,每股收益是检查假设的公司利润 “份额” 的好方法。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

这可能会让你想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看根据他们的估计描绘未来盈利能力的交互式图表。

How Do Unusual Items Influence Profit?

不寻常的物品如何影响利润?

Alongside that dilution, it's also important to note that Jilin Aodong Pharmaceutical Group's profit was boosted by unusual items worth CN¥139m in the last twelve months. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. Jilin Aodong Pharmaceutical Group had a rather significant contribution from unusual items relative to its profit to December 2023. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

除了这种稀释外,还需要注意的是,在过去的十二个月中,吉林奥东制药集团的利润是由价值1.39亿元人民币的不寻常项目提振的。我们不能否认更高的利润通常会让我们感到乐观,但如果利润是可持续的,我们更愿意这样做。当我们分析全球绝大多数上市公司时,我们发现重大不寻常的事项往往不会重演。这正如你所预料的那样,因为这些增强被描述为 “不寻常”。吉林奥东药业集团截至2023年12月的不寻常项目对其利润的贡献相当可观。在其他条件相同的情况下,这可能会使法定利润成为衡量潜在盈利能力的不良指导。

Our Take On Jilin Aodong Pharmaceutical Group's Profit Performance

我们对吉林奥东药业集团盈利表现的看法

To sum it all up, Jilin Aodong Pharmaceutical Group got a nice boost to profit from unusual items; without that, its statutory results would have looked worse. On top of that, the dilution means that its earnings per share performance is worse than its profit performance. For the reasons mentioned above, we think that a perfunctory glance at Jilin Aodong Pharmaceutical Group's statutory profits might make it look better than it really is on an underlying level. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. Every company has risks, and we've spotted 3 warning signs for Jilin Aodong Pharmaceutical Group you should know about.

综上所述,吉林奥东药业集团从不寻常的项目中获得了不错的利润提振;如果没有这些,其法定结果就会变得更糟。最重要的是,稀释意味着其每股收益表现不如其盈利表现。出于上述原因,我们认为,敷衍地看一眼吉林奥东药业集团的法定利润可能会使其看起来比实际水平要好。请记住,在分析股票时,值得注意所涉及的风险。每家公司都有风险,我们发现了吉林奥东药业集团的3个警示信号,你应该知道。

Our examination of Jilin Aodong Pharmaceutical Group has focussed on certain factors that can make its earnings look better than they are. And, on that basis, we are somewhat skeptical. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

我们对吉林奥东药业集团的审查侧重于某些可能使其收益看起来好于实际的因素。而且,在此基础上,我们有些怀疑。但是,还有很多其他方法可以让你对公司的看法。例如,许多人认为高股本回报率是有利的商业经济的标志,而另一些人则喜欢 “关注资金”,寻找内部人士正在买入的股票。因此,你可能希望看到这份免费收藏的拥有高股本回报率的公司,或者这份内部人士正在购买的股票清单。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发